MedTrace Logo

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

NCT02612623 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.

Conditions

  • Refractory Chronic Cough

Interventions

DRUG

Gefapixant

Gefapixant tablets administered by mouth twice daily for 8 weeks

DRUG

Placebo (for gefapixant)

Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks

Sponsors & Collaborators

  • Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-17
Primary Completion
2016-05-04
Completion
2016-05-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612623 on ClinicalTrials.gov